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Medicine and Surgery, Federico II University. Pu
nc-nd/4.0/).Abstract Until recently, in Italy, the use of continuous glucose monitoring (CGM) systems has
been limited, but is now rapidly increasing, including the so-called real-time CGM (rtCGM)
and the intermittently viewed CGM (iCGM), also called Flash Glucose Monitoring (FGM). These
technologies overcome many of the limitations of self-monitoring of blood glucose (SMBG) by
fingerprick and allow to go beyond HbA1c to check glucose control in diabetes. However, stan-
dardized protocols for applying and interpreting rtCGM and FGM data are lacking. In this paper,
we delineate a consensus amongst Italian diabetes physicians on the attributes of rtCGM and
FGM technologies, and introduce a consistent approach for their use by Italian healthcare profes-
sionals. Most experts consider rtCGM and FGM as two separate categories of interstitial subcu-
taneous fluid (ISF) sensing technologies, and see them as superior to SMBG. Furthermore, there is
strong consensus that rtCGM and FGM reduce hypoglycemia risk, increase the amount of time in
the target glucose range and augment treatment satisfaction. However, there is still no agree-
ment on the indication of the FGM for subjects who suffer asymptomatic hypoglycemia.
Consensus on the role of education in initiating and optimizing use of rtCGM/FGM and about
the interpretation of glucose trends was near unanimous, whereas no consensus was reached
on the statement that there are no disadvantages/risks of rtCGM/FGM. Some issues remain in
rtCGM/FGM management: a) risk of excessive correction of high or low glucose; b) risk of alert
fatigue leading to alert silencing or rtCGM termination; c) allergic reaction to the adhesive keep-
ing rtCGM or FGM sensors in place. The panel almost unanimously agreed that sensor accuracy
depends on multiple variables, that alarm setting should be individualized, and that globalurrello).
logy, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical
blished by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
422 D. Bruttomesso et al.Table 1 Distinct features of real time
Feature
Glucose sensing
Calibration
Fingerprick SMBG test required
Interference from acetaminophen
Duration of sensor life
Data update cycle
Immediate access to glucose values
Insulin dosing without
confirmatory fingerstick testing
Recommended Sensor site
High/low glucose alerts
Connection with CSII pumps
FGM, flash glucose monitoring; rtCGM
infusion.
a Manufacturers guidance, www.free
b Manufacturers guidance, www.my
c Manufacturers guidance: www.dex
d Manufacturers guidance https://s3glycemic profile represent an useful tool in interpreting glucose data. More clinical studies and a
wider use of these devices will increase the efficacy and effectiveness of continuous glucose
monitoring in Italy.
ª 2019 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the
Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Feder-
ico II University. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Most people with diabetes in Italy monitor their glucose
using SMBG. However, SMBG by intermittent capillary
sampling gives just snapshots of BG concentration. More-
over, due to pain and inconvenience, many patients may
not perform frequent SMBG [1,2] when it is needed.
The availability of continuous glucose monitoring
(CGM), through sensors inserted subcutaneously to mea-
sure glucose levels in the interstitial fluid, addresses
both issues by reducing patients’ discomfort and providing
vastly more glucose data [3]. Two types of continuous
glucose monitoring (CGM) systems are currently available:
real-time CGM (rtCGM) and intermittently viewed CGM
(iCGM), also called Flash Glucose Monitoring (FGM).
To maintain clear distinction throughout this article we
will refer to these technologies as rtCGM and FGM.
Both systems provide information about current and
previous glucose levels, as well as glucose trends andCGM and FGM systems.
rtCGM
ISF
Once or twice daily with SMBG
can be calibrated with a scan c
To calibrate and for insulin dos
and G6 don’t require SMBG tes
If glucose alerts and readings d
symptoms or expectations, or i
arrow is displayed (Dexcom G5
Yes with Dexcom G4/G5
Yes with Medtronic Enlite
No with Dexcom G6
No with Eversense
6 days (Enlite); 7 days (Dexcom
(Dexcom G6); 6 months (Evers
Every 5 min automatically
Button push
No (Enlite and Eversense)
Yes (Dexcom G5, G6)c,d
Abdomen (transcutaneous), up
arm (implantable)
Yes
Yes
, real-time continuous glucose mo
stylediabetes.co.uk/images/uploads
freestyle.com/provider/sites/all/them
com.com/fingersticks, accessed Nov
-us-west-2.amazonaws.com/dexcomanticipated future glycemic status. However each technol-
ogy has its own unique features, as shown in Table 1 and as
discussed in a 2017 international consensus on the use of
CGM [4]. Both rtCGM and FGM sensors collect real-time
glucose readings continuously. FGM provides this informa-
tion each time the user actively scans the sensor with the
device reader or via an app on their smartphone, whereas
rtCGM passively transmits this information without user
engagement. Furthermore, rtCGM alerts users of low and
high glucose, whereas FGM does not. In addition, FGM is
itself a blood glucose meter, making capillary blood glucose
measurement much more convenient when needed.
In Italy the most used rtCGM systems are the Dexcom
G5 (Dexcom, Inc.) and Medtronic Enlite (Medtronic, Inc.),
both using a transcutaneous sensor. Recently, the Ever-
sense (Senseonics, Inc.) rtCGM has been introduced, that
uses the first implantable subcutaneous sensor. At the time
of writing, only one FGM system was available, the
Freestyle Libre system (Abbott Diabetes Care).FGM
ISF
(Dexcom G6
ode)
Factory calibrated
ing (Dexcom G5
t for insulin dosing).
o not match
f no trend
, G6)
To confirm sensor reported hypoglycemia
or impending hypoglycemia; at times
of rapidly changing glucose; if symptoms
don’t match reading.
No
G5), 10 days
ense)
14 days (in EU)
10 days (in US)
When sensor is scanned with the reader
or smartphone app
By scanning
Yes (in EU)a
Yes (in US)b
per Back of upper arm
No
No
nitoring; ISF, interstitial fluid; CSII. Continuous subcutaneous insulin
/documents/FreeStyle_Libre_Manual.pdf, accessed November 2018.
es/provider20/pdf/FreeStyle-Libre-In-Service-Guide.pdf.
ember 2018.
pdf/G6-CGM-Users-Guide.pdf? accessed November 2018.
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have a positive effect on metabolic control [5e9], and on
the quality of life. However, the available evidence does
not cover exhaustively issues such as the perception of
differences between rtCGM/FGM vs SMBG, the use of
glucose values and trends to guide therapeutic decisions,
the ideal patient profile and the impact on everyday life.
In Italy, the use of glucose sensing technologies is
rapidly increasing, thus we intend here to establish a
consensus on the features of rtCGM and FGM, and to
validate a consistent approach to their use in clinical
diabetes care.
We used PubMed to survey the available literature for
evidence about rtCGM or FGM efficacy, accuracy, safety,
patient satisfaction and quality of life, compared either to
SMBG or other standard of care. Published randomized
clinical trials and observational studies (either cross-
sectional or prospective/retrospective) meta-analyses and
reviews were considered. Although not being strictly sys-
tematic, we are reasonably sure to have considered all
relevant papers, although we cannot exclude that some
may have escaped our notice. The summarized results of
this search are presented in the Survey of published evi-
dence below. This knowledge base was used to develop the
scope and content of the Delphi survey questionnaire
ultimately submitted to the expert panel for consensus. It
was devised in the form of 59 Likert statements that
probed agreement or disagreement against a selection of
points on the appropriate use of rtCGM or FGM as diag-
nostic or therapeutic devices in the management of people
with diabetes.
The implantable rtCGM sensor Eversense was not
included in the survey, due to limited published literature
and clinical experience. Similarly, there is no mention of
CGM in pregnant women, due to limited experience in this
context. In addition, the main focus of both the review and
the survey was on the use of rtCGM or FGM systems in
subjects on multiple daily insulin injections (MDI) or
continuous subcutaneous insulin infusion (CSII), but not
using sensor-augmented pump therapy (SAP).
Survey of published evidence
The impact of rtCGM and FGM on glycemic control in
diabetes
Several RCTs have shown that rtCGM and FGM improve a
range of outcomes in patients with type 1 or type 2
diabetes. Change in HbA1c is the most notable glycemic
indicator in current clinical practice, but other important
indicators are the time spent within the target glucose
range or in hypoglycemia, glycemic variability and treat-
ment satisfaction.
Change in HbA1c
Several studies (JDRF, DIAMOND, GOLD, SWITCH) have
shown that the use of rtCGM in adults and children with
type 1 diabetes reduces HbA1c levels (from 0.4 to 1.0%)
[10e13], irrespective of the insulin delivery method [5].To date FGM has been tested in 2 RCTs (IMPACT [14] and
REPLACE [15]) in adults with type 1 or insulin-treated type
2 diabetes. Neither study found significant differences in
HbA1c using FGM or SMBG. On the other side, a single-arm
prospective trial in children and teenagers with type 1
diabetes (SELFY) and a recent observational, real world
analysis on adult patients with type 1 diabetes found a
positive effect of FGM on HbA1c levels [16,17].
Time in target
The time with glucose levels within a target range in-
fluences both HbA1c and glycemic variability. For the
purposes of clinical studies, a target glucose range of
3$9e10$0 mmol/L (70e180 mg/dL) is typically specified.
The use of rtCGM in patients with type I diabetes increases
significantly the time in target. The JRDF CGM, DIAMOND,
SWITCH, IN CONTROL and REPLACE-BG studies all
reported increases of 1.3e2.3 h/day [10,11,13,18,19].
Regarding FGM the IMPACT and SELFY studies found a
significant increase of the time on target (0.9e1.0 h/day)
both in adults and children/teenagers [14,16]. On the other
side the REPLACE study [15] on FGM in adults with insulin-
treated type 2 diabetes found no significant effect on the
time in target.
Risk of hypoglycemia
Reducing the risk of hypoglycemia is a core objective for
managing people with diabetes, especially those on insulin
or on sulphonylureas. FGM and rtCGM both make a big
difference in this outcome. In the IMPACT and REPLACE
studies [14,15], the time that users of the FreeStyle Libre
FGM system spent below 3.9 mmol/L (70 mg/dL) was
reduced by 38% (IMPACT) and 43% (REPLACE), compared to
subjects using SMBG. Nocturnal hypoglycemia was also
reduced, by 40% in IMPACT [14], by 52% in REPLACE [15].
Similar results, using the Dexcom G4 Platinum rtCGM
system, were demonstrated in the DIAMOND and GOLD
studies [11,12].
CGM and FGM in individuals at high risk of
hypoglycemia
The use of rtCGM has a huge impact on individuals with
type 1 diabetes prone to severe hypoglycemia. The impact
of rtCGM has been tested in the HypoDE study [20] on
patients with impaired hypoglycaemia awareness or
severe hypoglycaemia treated with MDI, and in the IN
CONTROL study [18] on patients with impaired hypo-
glycaemia awareness. In HypoDE study rtCGM decreased
the number of hypoglycemic events by 72% with respect to
SMBG, and nocturnal hypoglycemia was reduced by
65% [10]. Similar results were seen in the IN CONTROL
study [18].
Sensor calibration, accuracy and wear life
Both rtCGM and FGMmeasure glucose in ISF rather than in
capillary blood as measured by SMBG meters. In this
context, it must be understood that blood and ISF are
different physiological compartments that follow different
424 D. Bruttomesso et al.dynamics [21]. This has several important consequences
for interpretation of rtCGM and FGM data. First, there is a
time-lag between blood and ISF readings as glucose takes
time to equilibrate between the two compartments. Under
steady state conditions this is estimated to be 5e10 min for
rtCGM [22] and FGM [23]. Secondly, the accuracy of the
sensor ISF glucose measurements is not constant, and will
vary depending on the blood glucose concentration and
the rate of blood glucose change [24,25]. In a head-to-head
comparison of the accuracy of FreeStyle Libre and
Dexcom G 5 it was recently shown that both systems
perform safely and efficiently but the DG5M sensor has
greater accuracy across all glucose values except in hypo-
glycaemia. Considering accuracy during blood glucose
swings, Dexcom G5 performed better than the FSL when
glucose increased, both slowly and rapidly. No differences
in accuracy were observed when glucose levels decreased
rapidly [26].
It will be interesting comparing G6 and new format of
Libre. There is no standard metric for quantifying the ac-
curacy of rtCGM or FGM sensors, and it is important to
understand the real-world conditions that influence ac-
curacy in order to ensure that treatment decisions based
on ISF sensor data are both effective and safe [27].
Most currently available rtCGM sensors have a 5e7 day
wear life, whereas the FreeStyle Libre FGM sensor has a
14-day wear life (Table 1). More recently, the Eversense
implanted sensor has demonstrated a 180-day life [28],
and the Dexcom G6 rtCGM with a 10-day wear life has
recently become available [29].
An important difference between rtCGM and FGM
systems is that, to maintain accuracy, rtCGM require the
user to perform once or twice-daily sensor calibration
using a SMBG test (see Table 1). The possible exception is
the Dexcom G6 that allows users to scan a calibration code
at start up, with optional SMBG calibration if the code is
lost. The efficacy of this process will become clear as users
build experience with the G6. In contrast, FGM sensors are
factory calibrated. Another notable difference between
rtCGM and FGM sensor technologies is that FGM sensors
operate at a much lower electrical potential than rtCGM
sensors [30], which improves their stability.
Trend arrows and insulin dosing decisions
An important advantage of rtCGM and FGM devices is that
they typically provide directional trend arrows alongside
the current glucose reading. Trend arrows provide infor-
mation on the direction and the rate of change (RoC) of ISF
glucose levels and are generated from the slope of ISF
glucose values over the previous 15 min. The pairing of a
current glucose reading with a directional trend arrow is a
powerful tool to assist with making diabetes self-
management decisions, not possible with SMBG testing.
One treatment area that still requires SMBG is that of
insulin dosing. The majority of rtCGM systems are not
approved for users to make insulin dosing decisions
without the need for an SMBG test to confirm blood-
glucose levels. However, at the time of writing 3 systemsare approved for insulin dosing without the need for an
adjunct SMBG test (both in the EU and the US): the
factory-calibrated FreeStyle Libre FGM system and the
Dexcom G5 and G6 rtCGM systems (see Table 1). At pre-
sent, for other systems with a similar or lower level of
accuracy it is required that SMBG measurements should be
performed to confirm rtCGM readings prior to making
insulin management decisions aimed at addressing acute
changes in glucose levels.
The utility of trend arrows for insulin dosing is a topic of
intense discussion. Recent surveys indicate that people
with diabetes using rtCGM rely on trend arrows to calcu-
late mealtime insulin boluses and also to make corrective
insulin dose adjustments between meals [31]. Importantly,
in response to RoC trend arrows, respondents using rtCGM
made significantly larger dose adjustments than would be
recommended by published algorithms for using RoC
trend arrows for insulin dose management [32,33].
Previously, subjects in clinical trials using rtCGM have
been provided with treatment algorithms for managing
insulin dosing decisions in line with trend arrows data
[10,34], and a range of real-world methods have been
proposed for adjusting insulin doses using trend arrows.
Methods proposed by Scheiner [35], Pettus/Edelman [36]
and Aleppo (specific to Dexcom G5) [37] rely on using
trend arrows to anticipate a future glucose value to
recommend an adjustment in insulin dose. Users can then
use their own predetermined insulin sensitivity factor to
add or subtract insulin, based on insulin sensitivity.
Recently ways to adjust insulin dosing have been proposed
also for the FreeStyle Libre [38].
To avoid potentially confusingmathematical calculations
to manage insulin dosing decisions, two groups have pro-
posed trend arrow adjustment tools (TAATs), in which each
trend arrow orientation is associated with a fixed, pre-
calculated dose-change to the regular mealtime insulin
bolus. The first of these was developed by Heffernan and
colleagues for children on CSII therapy, and directed them to
add or subtract either 0.5 or 1.0 unit of mealtime insulin
depending on the trend arrow orientation [39]. This TAAT
was effective in a pool of 20 children and adolescents.
Similarly, Klonoff and Kerr have proposed a TAAT for insulin-
treated adults [40], directing afixed1.0,1.5 or 2.0 unit insulin
adjustment depending on the direction and rate of change
shown by the trend arrows. Both TAATs assume a stan-
dardized insulin sensitivity factor, and that the rate and di-
rection of change in glucose for each trend arrow will be
consistent for around 45 min following a pre-meal reading.
Retrospective analysis and reporting
In addition to the immediate information provided by the
current glucose reading and the associated trend arrows, an
acknowledged benefit of rtCGM and FGM systems is that
they can store glucose readings for retrospective analysis of
glycemic control over weeks or months, depending on the
period over which a user has worn a sensor. Real time CGM
and FGM systems both automatically collect and save real-
time glucose measurements, however for FGM the user
Table 2 Minimum requirement for education and support to
effectively use of rtCGM and FGM systems.
1. Initial education on technical aspects of sensor application,
sensor reading and data entry.
2. Understanding the use of ancillary devices, such as smart-
phones and tablets, internet, desktop or laptop computers,
apps and other software.
3. Understanding that ISF and blood glucose are measured
differently, and the need to account for the sensor lag periods
during steady state and at times of rapid change in glucose
levels.
4. Education on real-time decision-making in response to
glucose readings and associated trend arrows, including
how to make therapeutic adjustments in response to rising or
falling glucose readings, and guidance on how to make
insulin-dosing decisions based on rtCGM/FGM data.
5. Education on all factors that might impact glucose readings
each day and between days, including: type and quantity of
food and drink; physical activity; insulin and other medica-
tions; stress or sickness.
6. For rtCGM systems, clear instruction on: how to effectively
calibrate the sensor and setting alerts and alert management,
in consultation with their HCP.
FGM, flash glucose monitoring; rtCGM, continuous glucose moni-
toring; ISF, interstitial fluid; HCP, healthcare professional.
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at least once every 8 h to ensure optimal data collection,
whereas rtCGM systems automatically transmit the data to
the reader or smartphone.
Real time CGM and FGM systems each have device-
specific reporting tools that can provide data on collections
of time-stamped glucose readings and trends over a single
day, or many days. An important development for retro-
spective analysis of rtCGM/FGM profiles has been the
introduction of the ambulatoryglucose profile (AGP), which
is an internationally agreed standard for summarizing and
interpreting daily glycemic patterns using large amounts of
data collected from rtCGM or FGM systems [41,42].
The AGP displays large amounts of glucose data as if all
the readings had occurred in a single 24-h period - the
so-called ‘modal’ day. A profile can be created from as little
as 5 days of such data or from as much as 3-months. Such
‘global’ profiles can provide important feedback on hypo-
glycemia, especially nocturnal patterns of low glucose, as
well as periods of glucose variability, including post-
prandial peaks. The impact of insulin doses, meals, exer-
cise, stress and other variables can also be assessed using
profiles that cover single days or more-extended periods
to examine the longer-term outcomes of treatment
changes. A limitation of the AGP and other modal reports
is that they work best if patients use their rtCGM/FGM
devices to log daily actions such as insulin doses, meals,
snacks, exercise, work, and sleep.
Patient satisfaction with rtCGM and FGM
Insulin therapy requires that frequent glucose monitoring
is part of achieving tight glycemic control. However, for
many people with diabetes, poor engagement with SMBG
can be a barrier to optimal glucose control [43]. Patient
reported outcomes during clinical studies using rtCGM
indicate improved diabetes treatment satisfaction and
overall sense of well-being [12]. Significantly, fear of
hypoglycemia is reduced by rtCGM [12]. rtCGM Satisfac-
tion Scale scores for subjects in clinical studies also indi-
cate a positive impact on both treatment benefits and
quality of life indices [11]. For FGM, in each of the IMPACT,
REPLACE and SELFY studies [14e16] the intervention
group indicated a positive impact of FGM compared to
SMBG in terms of use of the system, improved diabetes
treatment satisfaction scores, and diminished anxiety for
children or adults with type 1 or type 2 diabetes.
Patient education
In real-world settings many rtCGM or FGM users may
struggle to sustain prolonged use because of various con-
cerns over: accuracy; device education; frequency of alerts
and; interruptions to daily life. A qualitative meta-analysis
of available studies on how people with type 1 diabetes
live on a daily basis with rtCGM indicate that, alongside
the acknowledged healthcare benefits, there are a range of
physical, emotional and social issues that must be
managed by rtCGM users [44]. There is therefore aconsiderable need to ensure that implementing rtCGM or
FGM for people with diabetes is accompanied by education
and support measures that improve the ability of the user,
both to optimize their use of the technology and to set
their expectations in line with long-term use of rtCGM or
FGM. These should include the elements listed in Table 2.Methods
Study design
Delphi method
To reach a consensus, a modified Delphi method was used.
Delphi is a structured method that can be used to obtain
consensus among medical experts to develop clinical
guidelines, standards of care or clinical indicators [45,46].
The expert participants freely, individually and anony-
mously provide their opinion, through one or more rounds
of discussion. The process usually concludes when an
agreement on the discussed topic has been achieved. In this
study, each expert expressed their level of agreement ac-
cording to the following 5-point Likert scale: 1Z absolutely
disagree, 2 Z disagree, 3 Z agree, 4 Z more than agree,
5 Z absolutely agree. We considered a positive consensus
was reachedwhen the sum of items 1 and 2 (Disagree) or 3,
4 and 5 (Agree) reached 66%. No consensus was reached
when the sum of the responses for a negative consensus (1
and 2) or a positive consensus (3, 4 and 5) was <66%.
Development and validation of the Delphi
questionnaire
The Delphi method was applied in a 4-stage process. (1)
Literature research was undertaken covering the applica-
tion and utility of rtCGM and FGM in the management of
Table 3 Topic areas selected and validated for inclusion in the
Delphi questionnaire.
1. Clinical/therapeutic perception of FGM and rtCGM in com-
parison with SBMG
2. Use of FGM/rtCGM or SMBG for therapeutic decisions and
management
3. Calibration procedures
4. Sensor accuracy
5. Patient profile for rtCGM/FGM usage
6. Educational programs for clinicians and patients
7. Trend arrows interpretation
8. Information provided by rtCGM and FGM and data analysis
9. Disadvantages, risks and contraindications of FGM and
rtCGM
10. Alerts setting
FGM, flash glucose monitoring; rtCGM, real time continuous glucose
monitoring; SMBG, self-monitoring of blood glucose.
426 D. Bruttomesso et al.type 1 or insulin treated type 2 diabetes (see above). Based
on this research, a questionnaire was developed that
contained a list of items and statements aimed to test the
attitude and opinion of Italian clinicians on the appro-
priate use of rtCGM or FGM as diagnostic/therapeutic
devices in the management of people with diabetes. (2)Table 4a Results of the Delphi method survey of 74 expert diabetes phy
Survey quesƟon group
1. rtCGM or FGM technologies
1.1 Provide informaƟon on glycemic control, not achievable with SMBG.
1.2 Provide informaƟon (glycemic profile, rate of glucose changes and alerts) that migh
FGM, over SMBG. 
1.3 Provide clinical benefits, thanks to real-Ɵme therapeuƟc decisions. 
2. PaƟents using FGM have to measure capillary blood glucose levels in order to take a th
2.1 Symptoms do not match with sensor glucose measurement.
2.2 Hypoglycemia needs to be confirmed
2.3 Glucose levels are rapidly changing
3. PaƟents using a rtCGM device not authorized as a subsƟtute for SMBG, have to measu
3.1 Determine the insulin dose
3.2 Confirm and treat hypoglycemia
3.3 Perform device calibraƟon
4. Comparing rtCGM and FGM systems
4.1 FGM has different features compared to rtCGM
4.2 FGM might be considered as a CGM on demand
4.3 FGM could be considered as a real Ɵme CGM
5. CalibraƟon procedure
5.1 It can be performed at every moment of the day
5.2 It doesn’t bias glucose measurement
5.3 It might represent a limiƟng factor to paƟent’s compliance
5.4 It might represent a limiƟng factor for paƟent’s saƟsfacƟon
5.5 If factory calibrated (as for FGM), is more accurate, since it prevents paƟent’s error
6. Sensor accuracy
6.1 It depends on glycemic levels and the rate of blood glucose changes
7. rtCGM or FGM, compared to SMBG
7.1 Decrease glycated hemoglobin amounts
7.2 Increase the amount of Ɵme that glucose levels are within the target glycemic rang
7.3 Reduce hypoglycemia risk
7.4 Increase treatment’s saƟsfacƟon
7.5 Have a benefit directly proporƟonal to the frequency of use
8. rtCGM or FGM
8.1  FGM is suitable for type 1 diabetes paƟents, with asymptomaƟc hypoglycemia
8.2 rtCGM is suitable for type 1 diabetes paƟents, with asymptomaƟc hypoglycemia
8.3 rtCGM and FGM  are suitable for type 1 diabetes paƟents with unsaƟsfactory meta
8.4 rtCGM and FGM are beneficial for both type 1 or type 2 diabetes paƟents using eithThese statements were reviewed by an advisory board of
10 Italian experts in diabetes (the authors of this paper).
After discussion, the advisory board rephrased and
modified the questionnaire, obtaining 17 final items, each
detailed in 1 or more statements, as specified in the results
section. (3) The questionnaire was then submitted to 14
external validators. Following validators comments, 16
items were defined according to the topic areas listed in
Table 3. (4) The finalized Delphi questionnaire (Tables
4aec) was electronically delivered to 74 Italian diabetes
specialists, expert in rtCGM and FGM, working in separate
outpatient diabetes centers (58 adult and 16 pediatric).Results and discussion
A consensus was reached against all but two of the items
in the survey questionnaire, in that >66% of responses
either indicated agreement with each statement by se-
lection of items 3, 4 or 5 on the Likert scale, or indicated
disagreement by selecting items 1 or 2. This level of
consensus was achieved after a single round of polling.
Although we did not reach consensus for two items (8.1
and 14.1) in the present study, we did not proceed for a
second Delphi round because of limited information fromsicians from diabetes centres in Italy: question groups 1e8.
1 2 3 4 5 Agree Disagree
0 2 3 16 53 97% 3%
t improve the efficacy of rtCGM or 1 2 1 24 46 96% 4%
0 2 17 28 27 97% 3%
erapeuƟc decision if:
1 3 5 17 48 95% 5%
0 2 7 16 48 96% 3%
0 7 13 20 34 91% 9%
re capillary glucose blood levels to:
1 8 17 22 26 88% 12%
1 3 17 19 34 95% 5%
3 5 5 8 53 89% 11%
0 4 14 21 35 95% 5%
4 11 27 16 16 80% 20%
15 37 13 4 5 30% 70%
29 22 13 4 6 31% 69%
18 32 13 7 4 32% 68%
1 17 26 22 8 76% 24%
0 20 23 23 8 73% 27%
s 0 19 25 25 5 74% 26%
0 6 19 25 24 92% 8%
0 7 25 29 13 91% 9%
e 0 0 17 38 19 100% 0%
0 1 17 29 27 99% 1%
0 0 12 38 24 100% 0%
0 0 2 21 51 100% 0%
15 18 16 11 14 55% 45%
0 0 3 22 49 100% 0%
bolic control 0 2 18 24 30 97% 3%
er MDI or CSII 0 3 13 29 29 96% 4%
Response (n=74) Consensus score
Table 4b Results of the Delphi method survey of 74 expert diabetes physicians from diabetes centres in Italy: question groups 9e13.
Survey queson group 1 2 3 4 5 Agree Disagree
9. Regarding the educaon for the use of rtCGM/FGM
9.1 Paent needs to be instructed on how to insert/remove the sensor, to use the transmier and receiver and ancillary 
devices (smartphones, internet, computer, soware)
0 0 3 14 57 100% 0%
9.2 Paent needs to be instructed on how to interpret sensor measurements and to take appropriate acons 0 0 4 5 65 100% 0%
9.3 Paent needs to be trained on how to respond to real-me informaon, received by the sensor 0 0 3 6 65 100% 0%
9.4 Paents needs to accurately specify food, physical acvity, insulin/medicaons and other events that might cause a 
change in blood glucose levels. It is important to contextualize rtCGM and FGM data
0 2 9 10 53 97% 3%
9.5 Efficacy depends on the ability of the paent to properly use sensor measurements 0 0 4 15 55 100% 0%
9.6  With a poor training, paents might take risky therapeuc adjustments 0 0 10 12 52 100% 0%
9.7 Diabetes healthcare provider community need to set up educaonal courses for an appropriate use of rtCGM and FGM 
devices
0 1 2 8 63 99% 1%
10. The therapeuc management through rtCGM/FGM needs to take into consideraon that:
10.1 With the same glucose level, insulin doses might widely vary, according to glycemic trend 0 0 14 31 29 100% 0%
10.2 In order to adjust real me insulin doses, paents needs to take into consideraon trend arrows informaon (and alerts, 
if available)
0 0 5 27 42 100% 0%
10.3 When determining insulin dose, the paent needs to take into consideraon the expected glucose value, based on the 
trend arrow, rather than the absolute glucose value
0 0 15 32 27 100% 0%
11. Regarding rtCGM/FGM trend arrows: 0%
11.1 It is mandatory to know differences among devices, on how trend arrows are displayed and defined 0 0 11 23 40 100% 0%
11.2 When using trend arrows, variables to take into consideraon are: quality and amount of meal’s composion, physical 
acvity performed or to perform (intensity and length), medicaons increasing glucose levels, stress level and comorbidies
0 0 13 24 37 100% 0%
12. The glycemic profile analysis measured by rtCGM/FGM in the last 3-24 hours, provides informaon on:
12.1 Efficacy of prandial/correconal bolus 0 1 13 27 33 99% 1%
12.2 Effecveness of meals components 0 2 18 26 28 97% 3%
12.3 The presence of post-prandial peaks 0 2 18 24 30 97% 3%
12.4 Physical acvity’s effects 0 0 9 26 39 100% 0%
12.5 Stress impact 0 2 13 25 34 97% 3%
12.6 Night glycemic paerns 0 3 7 19 45 96% 4%
12.7 Basal insulin dose correctness 0 4 9 28 33 95% 5%
13. The retrospecve analysis of rtCGM/FGM data needs to consider:
13.1 Only global glycemic profiles 21 39 8 6 0 19% 81%
13.2 The analysis of global glycemic profiles, at first, and daily glycemic profiles, aerwards 0 0 10 33 31 100% 0%
13.3 A deep daily analysis is necessary especially when there is a wide glycemic variability, which makes difficult to idenfy 1 1 10 23 39 97% 3%
Response (n=74) Consensus score
Continuous glucose monitoring in the management of diabetes 427the literature to assess these items. We will examine in
the discussion section the topics that did not achieved
consensus. The Delphi method survey response data is
provided in Table 4aec and discussed below.
Clinical/therapeutic perception of FGM and rtCGM in
comparison with SBMG
Perceptions of value for both rtCGM and FGM are high
compared to SMBG. 97% of respondents agreed that both
technologies are superior to SMBG (Table 4a, section 1).Table 4c Results of the Delphi method survey of 74 expert diabetes phys
Survey quesƟon group
14. Regarding disadvantages and risks of rtCGM/FGM, I believe that:
14.1 There is no disadvantage/risk
14.2 There is an excess of hypo- and hyperglycemia correcƟon
14.3 PaƟent might silence rtCGM alerts or underuse the device, as a consequence of th
14.4 There is an allergic reacƟons and irritaƟon from the adhesive
15. rtCGM/FGM  are contraindicated:
15.1 In paƟents not considered able to manage the device
16. Regarding alerts seƫngs, I believe that:
16.1 Hypo- and hyperglycemia levels do not represent the target glycemic range of the 
16.2 Hypo- and hyperglycemia level alert seƫngs are equal among paƟents
16.3 Hypo- and hyperglycemia level alert seƫngs depend on the degree of paƟent’s  gly
16.4 It is recommended to set the hypoglycemia alert of  10-20 mg/ml, higher than the 
16.5 It might be useful to set alerts with diverse thresholds for Hypo- and hyperglycemiThis sense of value is founded in the ability of both rtCGM
and FGM to provide information on glycemic profiles and
rate of glucose change not achievable with SMBG (96%
consensus). There was strong consensus (97%) that these
features can provide clinical benefits, as they would enable
users to make real-time therapeutic decisions. In addition,
there was clear consensus in the expert panel on specific
circumstances that require fingerprick SMBG testing in
both rtCGM and FGM users (Table 4a, sections 2 and 3).
However, rtCGM and FGM are distinct technologies
with different distinguishing features. rtCGM sensorsicians from diabetes centres in Italy: question groups 14e16.
1 2 3 4 5 Agree Disagree
6 40 15 9 4 38% 62%
0 9 26 20 19 88% 12%
e alerts 0 5 24 29 16 93% 7%
0 7 26 25 16 91% 9%
0 4 11 9 50 95% 5%
paƟent 0 6 30 18 20 92% 8%
40 30 2 2 0 5% 95%
cemic control 0 1 24 36 13 99% 1%
real paƟent’s threshold 3 12 32 20 7 80% 20%
a, at different Ɵmes of the day. 0 5 25 30 14 93% 7%
Response (n=74) Consensus score
428 D. Bruttomesso et al.require once- or twice-daily calibration using an SMBG
test, whereas FGM sensors are factory calibrated. The
majority of rtCGM systems are not approved for users to
make insulin dosing decisions without the need for an
SMBG test to confirm blood-glucose levels. FGM using the
FreeStyle Libre system is approved in the US and in the EU
for insulin dosing without the need for an adjunct finger-
prick blood test, as are the Dexcom G5 and G6 rtCGM
systems (see Table 1).
An important consequence of these distinctions is
confirmed by the expert panel in section 4 of the survey.
There was consensus that FGM is distinct from rtCGM
(95%) and cannot be considered as an rtCGM system (70%).
However, even though it is continually sensing, FGM was
considered to be an ‘intermittent’ CGM or a CGM ‘on
demand’ (80%), since it must be scanned to acquire this
data. Thus, there is clear differentiation in the opinion of
the expert panel between rtCGM and FGM as separate
categories of ISF sensing technologies.
Features not considered here and possibly important in
choosing the system better tailored for individual patients
include minimum age for use, indication for use in preg-
nancy, real-time remote monitoring (data sharig) [47].
Use of rtCGM/FGM versus SMBG for therapeutic decisions
and diabetes management
The evidence base supporting improved glycemic control
for users of rtCGM and FGM technologies is fully appre-
ciated by the expert diabetes physicians in this Italian
survey (Table 4a, Section 7). There was very strong
consensus, both that rtCGM and FGM will reduce hypo-
glycemia risk for users (99%) and also increase the amount
of time in the target glucose range (100%). This confidence
is important given that minimizing hypoglycemia is a
major part of clinical practice. Consensus that rtCGM and
FGM can both reduce HbA1c as part of care compared to
SMBG was also high (91%), even though the available RCT
data confirms this outcome for rtCGM rather than FGM,
which achieved this only in children and teenagers with
type 1 diabetes in a single arm, prospective trial [16]. The
overall confidence in these systems is reflected in the 100%
agreement that rtCGM and FGM will increase treatment
satisfaction among patients, which is again in line with the
patient-reported outcomes from RCTs.
Sensor calibration and accuracy
The need to use SMBG to calibrate rtCGM systems means
that strip use will be higher for rtCGM users, whereas FGM
is calibrated in the factory and the user does not need to
perform this task. This need for user calibration is a key
difference between rtCGM and FGM. Infrequent or incor-
rect calibration by patients using SMBG can potentially
reduce the accuracy of rtCGM, an issue that does not affect
FGM systems. These important aspects of rtCGM and FGM
were appreciated by the diabetes experts in the survey,
who showed strong consensus with these distinctions
(Table 4a, sections 3.1e3.3, 5.2, 5.5), and there wasagreement that this could also limit patient satisfaction
and compliance with rtCGM systems (sections 5.3, 5.4, 73%
and 76% consensus, respectively).
Perceptions of sensor accuracy of both rtCGM and
FGM technologies was probed directly as part of the ques-
tionnaire (Table 4a, section 6), and there was clear under-
standing and agreement (92%) that accuracy depends on a
range of variables, notably the glucose level and the rate of
blood glucose change [24,25]. This is an important consid-
eration. Since they measure glucose in ISF rather than in the
blood, there is no standard metric for quantifying
the accuracy of rtCGM or FGM sensors, and it is important
to understand the real-world conditions that influence
accuracy in order to ensure that treatment decisions based
on ISF sensor data are both effective and safe [27].Patient profile for rtCGM/FGM use
In terms of the type of patients for whom rtCGM or FGM
are suitable technologies, our survey clearly showed high
confidence in CGM as an effective system for improving
glycemic control in people with type 1 diabetes on MDI or
CSII, including those with asymptomatic hypoglycemia
(Table 4a, section 8). There was consensus that FGM was
effective in improving control in type 1 diabetes treated
with MDI or CSII. However, there was not agreement on
the indication of the FGM for subjects who suffer asymp-
tomatic hypoglycemia (Table 4a, question 8.1). This is
interesting, given the general notion that the absence of
alarms is one of the key differences between rtCGM and
FGM systems (Table 1). It is possible that the ever wider
use of FGM in clinical practice may render physicians more
confident on the global improvement of disease control,
including reduction of hyoglycemia risk.
Equally important to note is the 95% consensus that
rtCGM and FGM are both contraindicated in patients not
able to manage these systems (Table 4c, section 15). This is
a clear acknowledgement of the need for good engage-
ment with the different capabilities of the technology, as
outlined in several sections of the survey.The need for education to support use of rtCGM/FGM
Consensus on the role of education in initiating and
optimizing use of rtCGM/FGM amongst patients was near
unanimous. Each aspect of the training needs of patients,
as detailed in Table 2 was supported by 97%e100%
agreement (Table 4b, Sections 9). This consensus in-
dicates a central role for education that allows patients
and healthcare professionals to integrate rtCGM/FGM
into daily life with diabetes, and to make effective ther-
apeutic decisions. This is underlined by the fact that
100% of respondents agreed that poor training might
lead to patients making risky therapeutic adjustments
(Table 4b, section 9.6). Similarly, it was recognized that
the responsibility for providing education on rtCGM/
FGM lies with the healthcare provider community
(Table 4b, section 9.7).
Continuous glucose monitoring in the management of diabetes 429Interpretation of trend arrows
Two sections of the Delphi questionnaire probed the expert
panel on the issue of the application and utility of trend
arrows in glycemic management for rtCGM/FGM users
(Table 4b, sections 10, 11). Trend arrows add context to each
glucose reading such that different therapeutic decisions
may follow a reading at the same absolute glucose level.
This concept of ‘anticipated’ glucose based on upward or
downward trends is a key benefit for rtCGM/FGM and has a
critical impact on insulin dosing decisions (Table 4b, section
10), as evidenced by the recent publications on how best to
interpret trend arrow information in calculating safe and
effective mealtime insulin and correction doses [35e40].
The integration of trend arrows into daily decisions requires
both an understanding of how the glucose trend informa-
tion is displayed for each device, and the rate of change it
implies, as well as how different activities impact on glucose
trends and rates of change (Table 4b, section 11). For each
question in sections 10 and 11 there was a 100% consensus,
stressing the importance of this aspect of rtCGM and FGM
systems, and supported by the clear consensus for educa-
tion in these aspects of rtCGM/FGM (Table 4b, section 9).
Information provided by rtCGM and FGM and data
analysis
Glycemic data collected by rtCGM and FGM systems is
acknowledged to have high impact for daily glycemic
control. There was clear consensus that rtCGM/FGM can
provide feedback on activities that affect glycemic control
within 3 h, and also create 24-h profiles that reflect the
impact of prandial/correction doses of rapid-acting insulin,
as well as basal dose adjustments (Table 4b, sections 12.1,
12.7). Glycemic variability after meals (sections 12.2, 12.3)
and overnight (section 12.6) are agreed to be notable ca-
pabilities of rtCGM/FGM, as well as the effects of physical
activity and stress (sections 12.4, 12.5).
The responses focused on retrospective glycemic anal-
ysis using rtCGM/FGM were insightful. There was good
consensus (81%) that extended global glycemic profiles,
such as using AGP, should not be used as the only tools for
retrospective analysis (Table 4b, section 13.1). Rather, there
was 100% agreement that global profiles are a good place
to start but must be followed by assessment of daily gly-
cemic profiles in order to get as complete a picture of as
many aspects of glucose control as possible (Table 4b,
section 13.2). This is most emphasized when glycemic
profiles highlight wide glycemic variability, which makes it
hard to identify specific patterns and potential causes
(Table 4b, section 13.3). This reflects the growing inter-
national consensus on the place of global profiling tools
such as AGP in clinical practice [42,48,49].
Disadvantages, risks and contraindications of rtCGM
and FGM
The acknowledged benefits of rtCGM and FGM technolo-
gies are accompanied by risks and disadvantages that mustbe considered before they can be fully adopted. This is
reflected in section 14 of the Delphi survey. No consensus
was reached among the expert group against the general
statement that there are no disadvantages/risks of rtCGM/
FGM (Table 4c, section 14.1). That 38% of respondents
agreed with this statement is somewhat surprising, given
the general notion that every device which may impact
glucose monitoring and insulin therapy can have some
notes of caution, disadvantages and even contraindica-
tions. It is possible that, for some of the diabetes experts
who were surveyed, the accurate selection of patients to
be provided with glucose sensors can in fact prevent most
of the hypothetical disadvantages. In addition, it is possible
that more direct clinical experience may be necessary to
develop a full consensus on the balance between strengths
and weaknesses.
As regards specific disadvantages/risks, there was
strong consensus that three aspects of rtCGM/FGM could
be problematic: These were that: a) there is a risk of
excessive correction of high or low glucose (section 14.2);
b) the benefits of rtCGM alerts would be counterbalanced
if users developed so-called ‘alert fatigue’ and either
silence the alert function or disengage from using rtCGM
as a consequence (section 14.3); c) and that the adhesive
necessary to keep rtCGM or FGM sensors in place on the
skin can cause an allergic reaction (section 14.4). Each of
these is an acknowledged burden of living with rtCGM and
FGM and each must be addressed in education and
training at the point of initiating rtCGM and FGMwith new
users.
Alert settings
High and low-glucose alerts are another important
differentiating feature for rtCGM, as FGM systems do not
have this capability. These were investigated further in
Section 16. There was expert agreement that the alert
settings in rtCGM should be set to match the individual
glycemic needs of each patient, rather than use a standard
setting for all rtCGM users (section 16.2, 16.3). This
consensus also acknowledged that some patients might
need different low and high glucose alert settings at
different times of day (section 16.5). In an additional note
of caution, there was 80% agreement that low-glucose
alerts should be set at 10e20 mg/ml higher than the lower
limit of the target glycemic range for rtCGM users (section
16.5), to further avoid adverse hypoglycemia.
The availability of predictive alarms for the implantable
rtCGM Eversense may potentially improve diabetes
management and prevent excessive glucose variations.
However, there is no published literature to date and
limited clinical experience on this feature.
Conclusions
Technologies aiming at measuring interstitial glucose
concentrations have started a new era in the management
of people with diabetes, providing diabetes teams and
patients with glucose data and profile interpretation tools
430 D. Bruttomesso et al.which can improve metabolic control, optimize therapy
management and foster disease awareness and optimal life
choices in patients. In the first part of this paper we have
summarized the published evidence on the benefits of
FGM and rtCGM in people with diabetes. We have
considered available meta-analyses, reviews and original
papers. Literature search, however was not strictly sys-
tematic, so some data might be missing. In the second part,
the results of the Delphi approach suggest that the dia-
betes professional community in Italy has gained consid-
erable and uniform experience in clinical use of rtCGM and
FGM. There is clear perception of the superiority of both
rtCGM and FGM over SMBG, specifically for the advantages
in term of hypoglycemia reduction and improvement in
time in the target glucose range and treatment satisfac-
tion. The panel acknowledged the distinct features of FGM
and rtCGM: FGM sensors do not require calibration from
the patient, are allowed for non-adjunctive use in insulin
dosing and show no interference with acetaminophen,
but are not indicated in subjects with hypoglycaemia un-
awareness. On the other hand, rtCGM devices are provided
with alarms, can be connected with insulin pumps and
store glucose values independently of user scanning, but
most of them require periodic calibration and SMBG
confirmation for insulin dosing. There is also clear under-
standing of the limitations in rtCGM/FGM management,
including risk of excessive correction of abnormal glucose
values, risk of alert fatigue leading to discontinuation, and
potential skin allergic reaction. Unanimous consensus was
reached on the essential role of education in initiating and
optimizing use of rtCGM/FGM and in the interpretation
of glucose trends. As technology provides more and more
accurate and reliable tools, more clinical research projects
and a wider use of these devices will increase the expertise
of diabetes teams and ultimately improve everyday life in
people with diabetes.
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